0001213900-18-013186.txt : 20180928 0001213900-18-013186.hdr.sgml : 20180928 20180928160409 ACCESSION NUMBER: 0001213900-18-013186 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180927 FILED AS OF DATE: 20180928 DATE AS OF CHANGE: 20180928 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Essetifin SPA CENTRAL INDEX KEY: 0001092601 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15070 FILM NUMBER: 181094181 MAIL ADDRESS: STREET 1: VIA SUDAFRICA 20 CITY: ROME STATE: L6 ZIP: 00144 FORMER NAME: FORMER CONFORMED NAME: SIGMA TAU FINANZIARIA SPA DATE OF NAME CHANGE: 20030516 FORMER NAME: FORMER CONFORMED NAME: SIGMA TAU FINANZIARIA DATE OF NAME CHANGE: 19990805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CAVAZZA PAOLO CENTRAL INDEX KEY: 0001163608 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15070 FILM NUMBER: 181094182 MAIL ADDRESS: STREET 1: VIA TESSERETE, 10 CITY: LUGANO STATE: V8 ZIP: V8 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cavazza Enrico CENTRAL INDEX KEY: 0001525744 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15070 FILM NUMBER: 181094183 MAIL ADDRESS: STREET 1: VIA PONTINA KM 30,400 CITY: POMEZIA (ROME) STATE: L6 ZIP: 00040 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cavazza Francesca CENTRAL INDEX KEY: 0001525742 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15070 FILM NUMBER: 181094184 MAIL ADDRESS: STREET 1: VIA PONTINA KM 30,400 CITY: POMEZIA (ROME) STATE: L6 ZIP: 00040 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cavazza Silvia CENTRAL INDEX KEY: 0001525743 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15070 FILM NUMBER: 181094185 MAIL ADDRESS: STREET 1: VIA PONTINA KM 30,400 CITY: POMEZIA (ROME) STATE: L6 ZIP: 00040 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cavazza Preta Martina CENTRAL INDEX KEY: 0001718557 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15070 FILM NUMBER: 181094186 MAIL ADDRESS: STREET 1: VIA SUDAFRICA 20 CITY: ROME STATE: L6 ZIP: 00144 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERX BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0000707511 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521253406 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15245 SHADY GROVE ROAD STREET 2: SUITE 470 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-208-9191 MAIL ADDRESS: STREET 1: 15245 SHADY GROVE ROAD STREET 2: SUITE 470 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ALPHA 1 BIOMEDICALS INC DATE OF NAME CHANGE: 19950719 4 1 ownership.xml OWNERSHIP DOCUMENT X0306 4 2018-09-27 0 0000707511 REGENERX BIOPHARMACEUTICALS INC RGRX 0001092601 Essetifin SPA VIA SUDAFRICA, 20 ROME L6 00144 ITALY 0 0 1 0 0001163608 CAVAZZA PAOLO VIA TESSERETE, 10 LUGANO V8 00000 SWITZERLAND 0 0 1 0 0001525744 Cavazza Enrico VIA SUDAFRICA, 20 ROME L6 00144 ITALY 0 0 1 0 0001525742 Cavazza Francesca VIA SUDAFRICA, 20 ROME L6 00144 ITALY 0 0 1 0 0001525743 Cavazza Silvia VIA SUDAFRICA, 20 ROME L6 00144 ITALY 0 0 1 0 0001718557 Cavazza Preta Martina VIA SUDAFRICA, 20 ROME L6 00144 ITALY 0 0 1 0 Common Stock 2018-09-27 4 C 0 3133681 0.06 A 34989080 D Convertible Promissory Note (right to buy) 0.06 2018-09-27 4 C 0 150000 150000 D 2013-09-12 Common Stock 3133681 0 D On September 27, 2018, Essetifin S.p.A., an Italian corporation ("Essetifin"), exercised its option to convert the Convertible Promissory Note, originally issued on September 11, 2013 and reissued on March 13, 2018, in an initial principal amount of $150,000 (the "Note"), including all accrued but unpaid interest thereon, into shares of common stock, $0.001 par value per share (the "Common Stock"), of RegeneRx Biopharmaceuticals, Inc. (the "Company"). The Company issued a total of 3,133,681 shares of Common Stock to Essetifin upon conversion of the Note, including 633,681 shares of Common Stock issued in respect of the accrued but unpaid interest on the Note. As a result of the conversion and as of September 27, 2018, Essetifin directly owns 34,989,080 shares of Common Stock, which includes 3,133,681 shares of Common Stock that were issued upon conversion the Note. Dispositive power over the shares of Common Stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of Common Stock held by Essetifin except to the extent of any pecuniary interest therein. Exhibit List: Exhibit 99.1 - Joint Filers' Signatures Essetifin S.p.A. By: /s/ Marino Zigrossi 2018-09-28 /s/ Marino Zigrossi for Enrico Cavazza by power of attorney 2018-09-28 /s/ Marino Zigrossi for Francesca Cavazza by power of attorney 2018-09-28 /s/ Marino Zigrossi for Silvia Cavazza by power of attorney 2018-09-28 /s/ Marino Zigrossi for Martina Cavazza Preta by power of attorney 2018-09-28 /s/ Nicola Wullschleger for Paolo Cavazza by power of attorney 2018-09-28 EX-99.1 2 f4092718essetifinex99-1_reg.htm JOINT FILERS SIGNATURES

Exhibit 99.1

JOINT FILERS’ SIGNATURES

ESSETIFIN S.P.A.

By:	/s/ Marino Zigrossi
Name:	Marino Zigrossi
Title:	Managing Director
Date:	September 28, 2018

Enrico Cavazza

By:	/s/ Marino Zigrossi
Name:	Marino Zigrossi
Title:	Attorney-in-fact**
Date:	September 28, 2018

Francesca Cavazza

By:	/s/ Marino Zigrossi
Name:	Marino Zigrossi
Title:	Attorney-in-fact**
Date:	September 28, 2018

Silvia Cavazza

By:	/s/ Marino Zigrossi
Name:	Marino Zigrossi
Title:	Attorney-in-fact**
Date:	September 28, 2018

Martina Cavazza Preta

By:	/s/ Marino Zigrossi
Name:	Marino Zigrossi
Title:	Title: Attorney-in-fact**
Date:	September 28, 2018

Paolo Cavazza

By:	/s/ Nicola Wullschleger
Name:	Nicola Wullschleger
Title:	Attorney-in-fact
Date:	September 28, 2018

** Power of Attorney was previously filed with Securities and Exchange Commission as an exhibit to the Form 3/A filed on October 4, 2017, with respect to the common stock of Fennec Pharmaceuticals, Inc.